People News: AstraZeneca and Pfizer

AstraZeneca hired Pfizer's Martin Mackay to lead research and development, and Pfizer named Wyeth R&D chief Mikael Dolsten to lead its R&D efforts. Dolsten, who led Wyeth R&D from May 2008 through the close of the company's acquisition by Pfizer, becomes president, Pfizer Worldwide R&D. Mackay, who was president, PharmaTherapeutics R&D at Pfizer, becomes president of R&D at AstraZeneca, with responsibility for delivering new drugs and biologics. Replacing him at Pfizer is SVP and head of worldwide research for PharmaTherapeutics R&D Rod MacKenzie, who will add responsibility for Asia R&D strategy to his current duties leading small molecule research.